Item 8.01 – Other Events.
On September 29, 2020, Sesen Bio Inc. (the “Company”) received notice from the European Medicines Agency (“EMA”) that it has appointed the Rapporteur and Co-Rapporteur for the Company’s marketing authorization application (“MAA”) currently in preparation for Vicineum™ (oportuzumab monatox), the Company's lead product candidate. The Rapporteur and Co-Rapporteur are members of EMA’s Committee for Human Medicinal Products (the “CHMP”) and will jointly coordinate CHMP’s evaluation of the Company’s planned MAA for Vicineum.
Additionally, the Company’s pre-submission meeting with the EMA has been tentatively scheduled for October 23, 2020. The pre-submission meeting is a critical milestone in the preparation of a MAA and provides the Company with an opportunity to review key elements of the Company’s planned MAA submission with the EMA and discuss next steps.
The assignment of the Rapporteurs and the scheduling of the pre-submission meeting are pivotal mandatory steps in the regulatory process toward a potential MAA submission for Vicineum to the EMA.
The Company expects to complete all necessary pre-submission activities with the EMA by the end of 2020, and anticipates filing the MAA in early 2021, with potential approval anticipated in early 2022.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:
This Current Report on Form 8-K contains forward-looking statements, including, but not limited to, expectations regarding the timing of the Company’s pre-submission meeting with the EMA, expectations regarding the completion of all pre-submission activities with the EMA, expectations regarding the timing of the Company’s planned MAA submission for Vicineum and expectations regarding the timing of the potential EMA approval of the planned Vicineum MAA. These forward-looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. A further description of the risks and uncertainties relating to the business of the Company is contained in the Company’s most recent annual report on Form 10-K and the Company’s quarterly reports on Form 10-Q, as well as any amendments thereto reflected in subsequent filings with the SEC. The Company undertakes no duty or obligation to update any forward-looking statements contained in this report as a result of new information, future events or changes in its expectations.